The estimated Net Worth of John C Thomas is at least $2.08 Milhão dollars as of 4 January 2022. Mr. Thomas owns over 1,000 units of NantKwest Inc stock worth over $32,490 and over the last 9 years he sold NK stock worth over $1,859,291. In addition, he makes $188,098 as Independent Director at NantKwest Inc.
John has made over 12 trades of the NantKwest Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of NK stock worth $5,650 on 4 January 2022.
The largest trade he's ever made was exercising 277,725 units of NantKwest Inc stock on 26 May 2016 worth over $61,100. On average, John trades about 19,196 units every 73 days since 2015. As of 4 January 2022 he still owns at least 1,000 units of NantKwest Inc stock.
You can see the complete history of Mr. Thomas stock trades at the bottom of the page.
John C. Thomas Jr. serves as Independent Director of the Company since April 2014. Since 2018, Mr. Thomas has served as the Chief Financial Officer and Secretary of SmartPharm Therapeutics, Inc, a genetic research and development company. In late 2017, Mr. Thomas rejoined DemeRx, Inc., a privately held company developing non-additive treatments for drug addiction, as the Chief Financial Officer after previously being the Chief Financial Officer from 2010 to 2013. From 2001 until 2018, Mr. Thomas served as Chief Financial Officer and Secretary, and from 2001 to 2016 as a director of CorMatrix Cardiovascular, a privately held medical device company. He has also served as Chief Financial Officer, Secretary, and Director of Motion Reality, Inc., a motion capture and simulation company, since 1991. From 2012 until 2019, Mr. Thomas served as a director of Novelion Therapeutics, Inc. (formerly QLT, Inc.), a public company focused on rare diseases and was the Chairperson of their Audit and Risk Committee and Nominating and Governance Committee. During the past ten years, Mr. Thomas served as acting Chief Financial Officer for DemeRx, Inc., MRI Interventions, Inc., MiMedx Group, Inc., and DARA BioSciences and as a director of MRI Interventions, Inc. Between 1999 and 2012, Mr. Thomas served as a Trustee and subsequently the Chairman of the Finance Committee of The Walker School, a private school. Mr. Thomas is a Certified Public Accountant and graduated from the University of Virginia, McIntire School of Commerce.
As the Independent Director of NantKwest Inc, the total compensation of John Thomas at NantKwest Inc is $188,098. There are 5 executives at NantKwest Inc getting paid more, with Barry Simon having the highest compensation of $454,440.
John Thomas is 66, he's been the Independent Director of NantKwest Inc since 2014. There are 3 older and 4 younger executives at NantKwest Inc. The oldest executive at NantKwest Inc is Frederick Driscoll, 69, who is the Lead Independent Director.
John's mailing address filed with the SEC is C/O VIRIOS THERAPEUTICS, INC., 44 MILTON AVENUE, ALPHARETTA, GA, 30009.
Over the last 9 years, insiders at NantKwest Inc have traded over $20,345,739 worth of NantKwest Inc stock and bought 4,163,265 units worth $55,365,252 . The most active insiders traders include Patrick Cambridge Equities,..., Steve Gorlin, eBarry J. Simon. On average, NantKwest Inc executives and independent directors trade stock every 33 days with the average trade being worth of $5,362,832. The most recent stock trade was executed by Richard Adcock on 5 February 2021, trading 150,000 units of NK stock currently worth $4,873,500.
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.
NantKwest Inc executives and other stock owners filed with the SEC include: